The monoclonal antibody tildrakizumab, sold by Sun Pharma as Ilumya, is more cost-effective for treatment of moderate-to-severe psoriasis than a half dozen competitors, including top-selling adalimumab (Humira), according to data…
PSORIATIC ARTHRITIS (PSA) is a chronic inflammatory disease characterized by joint pain, stiffness, and swelling and clinically presents as axial or peripheral arthritis, dactylitis, and nail or skin lesions. Usually…
New topical treatments for psoriasis increasingly prove that vehicles matter, says an expert who spoke at the South Beach Symposium. Additional noteworthy developments include new fixed combinations and new molecules…
ULM Office of Sponsored Programs and Research Published 3:47 PM EST Feb 12, 2020The Office of Sponsored Programs and Research announces the University of Louisiana Monroe has received a grant…
In a new guidance statement, the Japanese Dermatological Association (JDA) offers recommendations for the use of 8 biologic agents for the treatment of psoriasis. The guidance was published in the…
The use of biologic and systemic agents for psoriasis treatment in the United States increased significantly from 2007 to 2016, according to study data published in the Journal of Dermatological…
Editor's Note: This story is part of a new series on HealthCentral called "Get Your Ph.D.!", which is geared toward people who've got the basics of their condition down and…
Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis KY1005 met both primary end points demonstrating: A clinically meaningful improvement in disease activity compared to…